News >

Emerging Trastuzumab Biosimilar May Promote Competition

Angelica Welch
Published: Tuesday, May 22, 2018

Dr. Elisavet Paplomata

Elisavet Paplomata, MD
Multiple trastuzumab (Herceptin) biosimilars are currently being developed in the United States. In the wake of the December 2017 approval of MYL-1401O (Ogivri; trastuzumab-dkst), Elisavet Paplomata, MD, believes that ABP 980 may be the next trastuzumab biosimilar to make it through the regulatory process in both the United States and Europe.

, Paplomata, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discussed ABP 980 and the impact that biosimilars may have on global access to cancer care.

OncLive: There are multiple trastuzumab biosimilars in development, and one is approved in the United States. Can you provide insight on this evolving area?

Paplomata: Biosimilars are different than generic drugs, which we are all very familiar with. Generic drugs are structurally the same drug as the parent drug. A biosimilar is a biologic product which may have a similar but different structure from the reference product, but has shown in phase III trials to have the same efficacy and safety.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication